Article
Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tract
2022-05-06
Abstract excerpt
The continual evolution of SARS-CoV-2 has challenged the efficacy of many COVID19 vaccines and treatment options. One strategy that evades viral escape is using the entry receptor, human Angiotensin-Converting Enzyme 2 (hACE2). Soluble hACE2 receptor domains show potential as decoys but genetic modifications are necessary to provide sufficient efficacy. However, these engineered constructs are potentially suscepti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bdac18a9-4c40-5821-aa14-3d4b9d1c939d
- DOI
- 10.1101/2022.05.05.490805
